631911-01-8

Basic information

• Product Name: 4-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER
• Synonyms: 4-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER;3-Methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine;3-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
• CAS NO: 631911-01-8
• Molecular Formula: C₁₃H₂₀BNO₂
• Molecular Weight: 233.11
• Mol File: 631911-01-8.mol

Chemical Properties

• Boiling Point: 356.434°C at 760 mmHg
• Flash Point: 169.366°C
• Appearance: /
• Density: 1.039g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: 2-8°C(protect from light)
• PKA: 4.35±0.10(Predicted)
• CAS DataBase Reference: 4-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER(631911-01-8)
• EPA Substance Registry System: 4-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER(631911-01-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 631911-01-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER is used as a synthetic intermediate for the development of nitrogen-containing heterocycles, specifically as FGFR inhibitors. FGFR (Fibroblast Growth Factor Receptor) inhibitors are a class of drugs that target the fibroblast growth factor receptor, which plays a crucial role in cell proliferation, differentiation, and migration. By inhibiting FGFR, these compounds can potentially treat various diseases, including cancer.
Used in Chemical Research:
4-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER is also used as a research compound in the field of organic chemistry. Its unique structure allows chemists to explore new synthetic pathways and develop novel molecules with potential applications in various industries, such as pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C13H20BNO2/c1-9-8-10(15)6-7-11(9)14-16-12(2,3)13(4,5)17-14/h6-8H,15H2,1-5H3

Upstream product

• 6933-10-4 amino-5-bromo-2-toluene 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 99-52-5 2-methyl-4-nitro-benzenamine 
• 73183-34-3 bis(pinacol)diborane 
• 7149-70-4 2-bromo-5-nitrotoluene 
• 883715-40-0 2-(2-methyl-4-nitrophenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 

Downstream Products

• 1357093-77-6 N-(4-(5-bromo-4-methoxypyridin-3-yl)-3-methylphenyl)methanesulfonamide 
• 1357094-08-6 N-(4-(5-cyano-4-methoxy-3-pyridinyl)-3-methylphenyl)methanesulfonamide 

Relevant articles and documents

Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors

The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is one of the three endoplasmic reticulum (ER) transmembrane sensors of the unfolded protein response (UPR) that regulates protein synthesis, alleviates cellular ER stress and has been implicated in tumorigenesis and prolonged cancer cell survival. In this study, we report a series of 2-amino-3-amido-5-aryl-pyridines that we have identified as potent, selective, and orally bioavailable PERK inhibitors. Amongst the series studied herein, compound (28) a (R)-2-Amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-ethylphenyl)-N-isopropylnicotinamide has demonstrated potent biochemical and cellular activity, robust pharmacokinetics and 70% oral bioavailability in mice. Given these data, this compound (28) was studied in the 786-O renal cell carcinoma xenograft model. We observed dose-dependent, statistically significant tumor growth inhibition, supporting the use of this tool compound in additional mechanistic studies.

PERK INHIBITORS FOR TREATING VIRAL INFECTIONS

Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I):

PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS

Provided herein are compounds of formula (I) as shown below, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.

PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS

Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions diseases, and disorders.

PERK INHIBITING COMPOUNDS

Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.

PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS

Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I):

PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS

Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I).

Small molecule compound

The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.

RAD51 INHIBITORS

This application is directed to inhibitors of RAD51, and methods for their use, such as to treat or prevent conditions involving mitochondrial defects.

PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS

The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical compositions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer.